Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes.

Autor: Naoum I; Department of Cardiology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel., Saliba W; Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel., Barnett-Griness O; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.; Statistical Unit, Lady Davis Carmel Medical Center, Haifa 3436212, Israel., Aker A; Department of Cardiology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel., Zafrir B; Department of Cardiology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Sep 19; Vol. 13 (18). Date of Electronic Publication: 2024 Sep 19.
DOI: 10.3390/jcm13185541
Abstrakt: Background: Real-world data on the implementation and prognostic impact of glucose-lowering drugs with proven cardiovascular benefits in patients with type 2 diabetes (T2D) following acute coronary syndrome (ACS) are limited. We investigated the utilization and treatment patterns of sodium-glucose contrasporter-2 inhibitors (SGLT2Is) and glucagon-like peptide-1 recepto-agonists (GLP1RAs) in patients with T2D experiencing ACS and analyzed their association with mortality and major adverse cardiovascular events (MACEs) including recurrent ACS, acute revascularization, heart failure, or ischemic stroke. Methods : We carried out a retrospective analysis of 9756 patients with T2D from a nationwide healthcare organization in Israel who were hospitalized with ACS between 01/2019 and 01/2022. Drug prescriptions were estimated pre-hospitalization, 90 days, and 1 year following hospitalization. The association between SGLT2I and/or GLP1RA treatment with MACE and mortality was investigated using a time-dependent Cox regression analysis with multivariable adjustment. Results : The prescription rates (pre-hospitalization, 90 days, and 1 year post-hospitalization) of GLP1RAs were 13%, 13.2%, and 18%, and those of SGLT2Is were 23.9%, 33.6%, and 42.7%, respectively. At 1 year, 13.9% of patients were prescribed both treatments. The use of SGLT2Is and/or GLP1RAs was higher in younger age groups and increased from 2019 to 2021 (38.1% to 59.2%). The adjusted hazard ratio for the association of pre- or post-hospitalization SGLT2I and/or GLP1RA treatment with mortality and MACE was 0.724 (0.654-0.801) and 0.974 (0.909-1.043), respectively. Conclusions : In the real-world practice of treating patients with T2D experiencing ACS, the implementation of SGLT2Is, particularly GLP1RAs, was suboptimal when prescribed both early and 1 year following hospitalization, emphasizing the need to improve medical care. Treatment with SGLT2Is and/or GLP1RAs was associated with a favorable impact on mortality but not MACE.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje